| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reviews |
1 Department of Pharmacology, University of Colorado School of Medicine, Denver, Colorado and 2 Department of Gynecology and Obstetrics, Medical School, J.W. Goethe-University, Frankfurt, Germany
Requests for reprints: Frank Eckerdt, Department of Pharmacology, University of Colorado School of Medicine, 4200 East 9th Avenue, Denver, CO 80262. Phone: 303-315-7681; Fax: 303-315-7160; E-mail: Frank.Eckerdt{at}UCHSC.edu and Klaus Strebhardt, Department of Gynecology and Obstetrics, Medical School, J.W. Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. Phone: 49-69-63016894; Fax: 49-69-63016364; E-mail: Strebhardt{at}em.uni-frankfurt.de.
| Abstract |
|---|
|
|
|---|
| Anaphase-Promoting Complex/Cyclosome Activity: Ordered Proteolysis of Mitotic Proteins, Including Polo-Like Kinase 1 |
|---|
|
|
|---|
| Liberating APC/C from Its Inhibitors |
|---|
|
|
|---|
Although Plk1 can contribute synergistically to the cyclin B/Cdk1mediated activation of the APC/C (6), this observation is not sufficient to explain the crucial role of Plk1/Plx1 in the activation of the APC/C. Intriguing insights have come from studies of the cytostatic factor (CSF) in Xenopus oocytes, where CSF activity prevents parthogenetic development by blocking exit from metaphase of meiosis II until fertilization (8). CSF activity has not been completely characterized, but it is known to involve APC/C inhibition. Because APC/CCdc20 activation is essential for the release from CSF arrest, the inhibition of APC/CCdc20 seems to be the ultimate function of the CSF. Recently, the APC/C inhibitors early mitotic inhibitor 1 and Emi2 (previously named XErp1) have emerged as candidate components of CSF activity. Emi2 seems to be the key element for CSF arrest in the oocyte, as specific inhibition of Emi2 leads to activation of the APC/CCdc20 (9). Importantly, this inhibition of Emi2 is mediated by the Xenopus Polo-like kinase Plx1 (10). In response to fertilization, Ca2+/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Emi2, thereby acting as a priming kinase for Plx1, which in turn promotes its degradation by phosphorylating Emi2 in a polo-box domaindependent manner (10, 11). These findings finally provide an explanation for the essential role of Plx1 for APC/C activation and subsequent CSF release (5). Unless an Emi2 homologue is identified in somatic cells, it seems that Emi1 is the major APC/C inhibitor in mitotic cells, where a strikingly similar mechanism can be observed. Emi1 regulates mitotic entry by inhibiting the APC/C, thereby allowing cyclin B accumulation. In mammalian cells, Plk1 also triggers the degradation of Emi1, suggesting that Plks have a conserved role in liberating the APC/C from its inhibitors (12, 13). Prior phosphorylation of Emi1 by cyclin B/Cdk1 potentiates the action of Plk1, suggesting that cyclin B/Cdk1 is a priming kinase for Plk1. These results are in agreement with our previous studies, providing the first evidence for the requirement of a priming kinase to ensure efficient phosphorylation of proteins by Plk1 (14). Phosphorylation of serine residues within the DSGxxS sequence of Emi1 by Plk1 generates a phospho-degron, which increases binding of Emi1 to the Skp1-Cullin-F-boxß-TRCP (SCFß-TRCP) ubiquitin ligase complex, leading to the formation of Emi1-ubiquitin conjugates (12, 13). Emi1 destruction activates the APC/C, thereby enabling the cell to degrade early APC/C targets like cyclin A. However, Plk1 activity might not be essential for cyclin A destruction because Plk1-depleted cells are still able to degrade cyclin A (2, 7). Possibly, this cyclin A degradation is due to incomplete Plk1 depletion as suggested by a novel study reporting a G2 arrest in synchronized HeLa cells when Plk1 is completely depleted (15). This idea is in line with the observation that cyclin B/Cdk1 serves as a priming kinase for Plk1, suggesting that in the presence of high cyclin B/Cdk1 activity, very low amounts of Plk1 might be sufficient to initiate Emi1 degradation. Still, increased Plk1/Plx1 activity accelerates mitotic progression in human cells and is sufficient for CSF release in Xenopus egg extracts in the absence of calcium (1, 10). Because Plk1 is overexpressed in a large variety of human cancers (1), it is likely that increased Plk1 activity might lead to premature activation of the APC/C, which in turn leads to genomic instability and thereby contributes to oncogenesis.
| Role of Plk1 in the Spindle Checkpoint-Regulated Activity of the APC/C |
|---|
|
|
|---|
Although the knowledge about the basic principles of spindle checkpoint control is improving, the exact mechanisms translating changes in tension and microtubule attachment at kinetochores into biochemical signals regulating checkpoint activity need further elucidation. Recent studies provide intriguing evidence for Plk1 playing a major role in this process, resulting in silencing of the spindle checkpoint and subsequent activation of the APC/C. Cdc20 is the target for inhibition of the APC/C by the spindle checkpoint whose signals originate at kinetochores. Importantly, kinetochores not under tension are specifically phosphorylated by Plk1 at an epitope recognized by the 3F3/2 antibody thereby creating the tension-sensing 3F3/2 phosphoepitope (18, 19). Moreover, Plk1 is required for the recruitment of the checkpoint protein Mad2 to kinetochores. Unattached kinetochores mediate checkpoint signals by activating the checkpoint kinase BubR1, which subsequently promotes the recruitment of a stable Mad1-Mad2 heterodimer leading to active Mad2 (16). Activated Mad2 and/or BubR1 associate with Cdc20, preventing it from activating the APC/C. Down-regulation of Plk1 by siRNA reduces the kinetochore-associated levels of both Mad2 and Cdc20 (18), further substantiating a role for Plk1 in the regulation of the spindle checkpoint. Still, the influence of Plk1 activity on the localization of Mad2 to kinetochores remains controversial. Although it was reported that Plk1 depletion leads to loss of Mad2 at kinetochores (18, 19), other groups observe an enrichment of Mad2 at kinetochores after Plk1 depletion (2, 20). Although this aspect requires further investigation, the involvement of Plk1 in the regulation of the spindle checkpoint seems established, because Plk1-depleted cells arrest in prometaphase with an activated spindle checkpoint, but these cells fail to arrest if Mad2 or BubR1 are codepleted (2). Taken together, these results suggest Plk1 as an antagonist for the inhibitory influence of the spindle checkpoint on APC/CCdc20 activity.
Cells treated with microtubule drugs, like nocodazole or Taxol, accumulate Plk1 at kinetochores probably in response to a loss of tension (18). The underlying mechanism is poorly understood. However, in Xenopus, localization of Plx1 at the kinetochore is under the control of an essential checkpoint kinase, monopolar spindle 1 (Mps1) (19). These observations indicate that Plk1 is both target and regulator of the spindle checkpoint whose essential function is to inhibit APC/CCdc20 and to block anaphase entry until chromosomes are properly attached to the mitotic spindle. This is of special interest because mutations in checkpoint genes were found in many chromosomal instability (CIN) cancer cell lines, indicating that mitotic checkpoint defects contribute to tumorigenesis likely by causing aneuploidy (reviewed in ref. 21).
| Deregulated Proteolysis and Genomic Instability |
|---|
|
|
|---|
Whereas the degradation of early APC/C targets like cyclin A depends on the timely destruction of Emi1, the destruction of later APC/C targets, like cyclin B and securin, is under the control of the spindle checkpoint. By targeting securin for degradation, the APC/C regulates sister chromatid separation. Although Plk1 is involved indirectly in all these scenarios by regulating the APC/C via Emi1 and the spindle checkpoint, it also directly regulates sister chromatid separation by targeting cohesin. Thus, the concerted action of Plk1 and APC/C ensures the proper division of the genetic material. Failure in this process will lead to aneuploidy, a characteristic feature of most tumor cells. Later in G1 phase, APC/CCdh1 targets the licensing factor cdc6 for destruction, an important step because overexpression of cdc6 results in re-replication and genetic alterations. Thus, regulation of APC/C activity controls the ordered proteolysis of cell cycle regulators, and deregulation of APC/C-mediated proteolysis likely leads to genomic instability (reviewed in ref. 3).
In summary, Plk1 triggers the activity of the APC/C-mediated proteolytic machinery in multiple ways (Fig. 1 ). In addition, Plk1 also directly regulates the stability of specific mitotic key components. While destruction of the Cdk1-inhibitory kinase Wee1 is orchestrated by different mitotic kinases, including Plk1, we found that Plk1 has also the ability to stabilize the peptidyl-prolyl cis/trans-isomerase Pin1 by phosphorylating Ser65 within its catalytic domain (22). Pin1 is known to regulate a broad spectum of biological processes and pathologic conditions such as cancer. Inhibition of Plk1 activity enhances the ubiquitylation of Pin1 and subsequently reduces the amount of Pin1 in human cancer cells.
|
| Acknowledgments |
|---|
| Footnotes |
|---|
We apologize to authors whose research articles could not be cited due to space constraints.
Received 1/30/06. Revised 3/30/06. Accepted 4/14/06.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. Rudolph, M. Steegmaier, M. Hoffmann, M. Grauert, A. Baum, J. Quant, C. Haslinger, P. Garin-Chesa, and G. R. Adolf BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity Clin. Cancer Res., May 1, 2009; 15(9): 3094 - 3102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chu, M. Alexiadis, and P. J. Fuller Proteasome Inhibition by Bortezomib Decreases Proliferation and Increases Apoptosis in Ovarian Granulosa Cell Tumors Reproductive Sciences, April 1, 2009; 16(4): 397 - 407. [Abstract] [PDF] |
||||
![]() |
S.-H. Pan, C.-C. Tai, C.-S. Lin, W.-B. Hsu, S.-F. Chou, C.-C. Lai, J.-Y. Chen, H.-F. Tien, F.-Y. Lee, and W.-B. Wang Epstein-Barr virus nuclear antigen 2 disrupts mitotic checkpoint and causes chromosomal instability Carcinogenesis, February 1, 2009; 30(2): 366 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Chi, K. Haller, M. D. Ward, O. J. Semmes, Y. Li, and K.-T. Jeang Requirements for Protein Phosphorylation and the Kinase Activity of Polo-like Kinase 1 (Plk1) for the Kinetochore Function of Mitotic Arrest Deficiency Protein 1 (Mad1) J. Biol. Chem., December 19, 2008; 283(51): 35834 - 35844. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. J. Steen, H. Steen, A. Georgi, K. Parker, M. Springer, M. Kirchner, F. Hamprecht, and M. W. Kirschner Different phosphorylation states of the anaphase promoting complex in response to antimitotic drugs: A quantitative proteomic analysis PNAS, April 22, 2008; 105(16): 6069 - 6074. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L Schmit and N. Ahmad Regulation of Mitosis via Mitotic Kinases: New Opportunities for Cancer Management Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 133 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yang, D. G. Camp II, M. A. Gritsenko, Q. Luo, R. T. Kelly, T. R. W. Clauss, W. R. Brinkley, R. D. Smith, and D. L. Stenoien Identification of a novel mitotic phosphorylation motif associated with protein localization to the mitotic apparatus J. Cell Sci., November 15, 2007; 120(22): 4060 - 4070. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Schmit and N. Ahmad Regulation of mitosis via mitotic kinases: new opportunities for cancer management Mol. Cancer Ther., July 1, 2007; 6(7): 1920 - 1931. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |